EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Efficacy and Safety of CKDB ‐ 501A in Treating Moderate‐To‐Severe Glabellar Lines: A Randomized, Double‐Blind, Active‐Controlled, Multi‐Center Phase III Trial

Sun Young Choi iD, Beom Joon Kim, Yang Won Lee, Won-Serk Kim, Yi Na Yoon, Jin Seop Kim

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70305 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Sun Young Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong-si, Korea. Hauptthemen laut MEDLINE: Skin Aging, Botulinum Toxins, Type A, Cosmetic Techniques, Neuromuscular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chong Kun Dang BiO Corporation (Seoul, Korea).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Botulinum toxin is a key treatment for dynamic wrinkles.

Objective

This study evaluates CKDB‐501A, a botulinum toxin completely free from animal‐derived components including human‐serum albumin, comparing its efficacy and safety to onabotulinumtoxinA (ONA) for the treatment of moderate‐to‐severe glabellar lines.

Methods

In this phase 3 trial, 300 subjects with moderate‐to‐severe glabellar lines were randomized to receive CKDB‐501A or ONA. The primary efficacy endpoint was the investigator‐assessed improvement rate for frowning at week 4, defined as a ≥ 2‐point improvement from baseline on the 4‐point Facial Wrinkle Scale (FWS). Secondary efficacy endpoints included photo‐assessed improvement rates and subjects' overall assessment and satisfaction. Safety was evaluated by the monitoring of adverse events (AEs) and neutralizing antibodies formation.

Results

At week 4, 80.69% of the CKDB‐501A group achieved a ≥ 2‐point improvement in FWS score versus 70.83% for ONA, confirming non‐inferiority (95% CI: 0.09–19.55, p = 0.0491). Secondary endpoints showed no significant differences between groups, with sustained efficacy up to 16 weeks. Approximately 70% maintained at least a 1‐point improvement. Photo‐assessed and subjects' overall improvement and satisfaction rates were consistent with primary findings. Both treatments had comparable safety profiles, with no AEs related to the local and distant spread of toxin, hypersensitivity reactions, or neutralizing antibodies formation.

Conclusion

CKDB‐501A is a safe and effective alternative to existing botulinum toxin products for treating moderate‐to‐severe glabellar lines, offering benefits of improved biocompatibility and reduced risk of allergic reactions. Clinicaltrials.gov : NCT05804656.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin AgingBotulinum Toxins, Type ACosmetic TechniquesNeuromuscular AgentsHumansFemaleMiddle AgedDouble-Blind MethodMaleAdultTreatment OutcomePatient SatisfactionForeheadAgedSeverity of Illness Index

Stichwörter der Autor:innen

Asiananimal‐origin freebotulinum toxinglabellar lineshuman serum albumin free

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Dermatology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong-si, Korea.
  • Department of Dermatology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
  • Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea.
  • Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Sun Young Choi

Förderung

  • Chong Kun Dang BiO Corporation (Seoul, Korea)

Zitieren

APA

Choi, S. Y., Kim, B. J., Lee, Y. W., Kim, W. S., Yoon, Y. N., & Kim, J. S. (2025). Efficacy and Safety of CKDB ‐ 501A in Treating Moderate‐To‐Severe Glabellar Lines: A Randomized, Double‐Blind, Active‐Controlled, Multi‐Center Phase III Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70305

Vancouver

Choi SY, Kim BJ, Lee YW, Kim WS, Yoon YN, Kim JS. Efficacy and Safety of CKDB ‐ 501A in Treating Moderate‐To‐Severe Glabellar Lines: A Randomized, Double‐Blind, Active‐Controlled, Multi‐Center Phase III Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70305

BibTeX
@article{Choi2025,
  author = {Choi, Sun Young and Kim, Beom Joon and Lee, Yang Won and Kim, Won-Serk and Yoon, Yi Na and Kim, Jin Seop},
  title = {Efficacy and Safety of CKDB ‐ 501A in Treating Moderate‐To‐Severe Glabellar Lines: A Randomized, Double‐Blind, Active‐Controlled, Multi‐Center Phase III Trial},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70305}
}
Kostenlos starten →